{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:32:09Z","timestamp":1789475529185,"version":"build-2803163510"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>The optimal multimodal strategy for esophageal and gastro-esophageal junction (GEJ) adenocarcinoma remains uncertain. Evidence comparing peri-operative FLOT chemotherapy with neoadjuvant chemoradiotherapy (CRT) is limited, and real-world data specific to true esophageal and Siewert I\u2013II adenocarcinoma are sparse. This study evaluated contemporary oncological and surgical outcomes following FLOT or CRT in two high-volume international centers. A bi-national retrospective cohort study was conducted including patients treated between 2012 and 2024 who received neoadjuvant therapy followed by esophagectomy for locally advanced esophageal or Siewert I\/II GEJ adenocarcinoma. Clinical, pathological, peri-operative, and survival outcomes were compared between peri-operative FLOT and CRT. Survival was analyzed using Kaplan\u2013Meier and Cox regression; recurrence was evaluated using Fine\u2013Gray competing-risk modeling. Of 402 patients, 139 (34.6%) received CRT and 263 (65.4%) FLOT. Baseline characteristics were similar except for a higher ASA class in the CRT cohort. Three-stage esophagectomy was more frequent after CRT, while FLOT patients more commonly underwent minimally invasive or hybrid procedures. Major postoperative morbidity was comparable after adjustment. Neoadjuvant completion exceeded 85% in both groups, while adjuvant FLOT completion was achieved in 66%. Pathological complete response rates were similar. FLOT yielded higher lymph node harvests but more advanced ypTNM staging; CRT produced more ypT1 tumors. R0 resection rates were equivalent. Adjusted overall survival favored FLOT (HR 1.67; P\u2009=\u20090.0025), with benefits maintained at 3 and 5\u00a0years. Recurrence risk was lower after FLOT. Stage-stratified analysis demonstrated advantages for FLOT in ypTNM II\u2013III disease. In this large real-world cohort, peri-operative FLOT was associated with superior adjusted survival compared with CRT, despite similar Pathological Complete Response (pCR) and resection outcomes. These findings support FLOT as an effective multimodal strategy for esophageal and junctional adenocarcinoma.<\/jats:p>","DOI":"10.1093\/dote\/doag052","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:30:08Z","timestamp":1778585408000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-world outcomes of FLOT versus Chemoradiotherapy for Esophageal, Type I and II Junctional Tumors: A Bi-Center International Study"],"prefix":"10.1093","volume":"39","author":[{"given":"Sam","family":"Alhayo","sequence":"first","affiliation":[{"name":"Upper GI Unit, Department of Surgery, Royal Adelaide Hospital , Adelaide ,","place":["Australia"]},{"name":"Department of Upper GI Surgery, Queen Elizabeth Hospital, University Hospital NHS Foundation Trust , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Seabourne","sequence":"additional","affiliation":[{"name":"Department of Upper GI Surgery, Queen Elizabeth Hospital, University Hospital NHS Foundation Trust , Birmingham ,","place":["UK"]},{"name":"Department of Surgery, College of Medicine and Health-University of Birmingham , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Upper GI Surgery, Queen Elizabeth Hospital, University Hospital NHS Foundation Trust , Birmingham ,","place":["UK"]},{"name":"Department of Surgery, College of Medicine and Health-University of Birmingham , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Shepherdson","sequence":"additional","affiliation":[{"name":"Upper GI Unit, Department of Surgery, Royal Adelaide Hospital , Adelaide ,","place":["Australia"]},{"name":"School of Public Health, University of Adelaide , Adelaide ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Edwards","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Adelaide , Adelaide ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Stranz","sequence":"additional","affiliation":[{"name":"Upper GI Unit, Department of Surgery, Royal Adelaide Hospital , Adelaide ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalvin","family":"Prasad","sequence":"additional","affiliation":[{"name":"Upper GI Unit, Department of Surgery, Royal Adelaide Hospital , Adelaide ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Trochsler","sequence":"additional","affiliation":[{"name":"Upper GI Unit, Department of Surgery, Royal Adelaide Hospital , Adelaide ,","place":["Australia"]},{"name":"School of Public Health, University of Adelaide , Adelaide ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fackrell","sequence":"additional","affiliation":[{"name":"Department of Upper GI Surgery, Queen Elizabeth Hospital, University Hospital NHS Foundation Trust , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L","family":"Whiting","sequence":"additional","affiliation":[{"name":"Department of Upper GI Surgery, Queen Elizabeth Hospital, University Hospital NHS Foundation Trust , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewen A","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Department of Upper GI Surgery, Queen Elizabeth Hospital, University Hospital NHS Foundation Trust , Birmingham ,","place":["UK"]},{"name":"Institute of Immunology and Immunotherapy, University of Birmingham , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Kanhere","sequence":"additional","affiliation":[{"name":"Upper GI Unit, Department of Surgery, Royal Adelaide Hospital , Adelaide ,","place":["Australia"]},{"name":"School of Public Health, University of Adelaide , Adelaide ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"1","key":"2026052912571875200_ref1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1759-7714.14745","article-title":"Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040","volume":"14","author":"Liu","year":"2023","journal-title":"Thorac Cancer"},{"issue":"3","key":"2026052912571875200_ref2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2026052912571875200_ref3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cac2.12645","article-title":"Current status and perspectives of esophageal cancer: a comprehensive review","volume":"45","author":"Jiang","year":"2025","journal-title":"Cancer Commun"},{"issue":"1","key":"2026052912571875200_ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"","year":"2006","journal-title":"N Engl J Med"},{"issue":"22","key":"2026052912571875200_ref5","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"2026052912571875200_ref6","doi-asserted-by":"publisher","first-page":"103432","DOI":"10.1016\/j.eclinm.2025.103432","article-title":"Radiation dose escalation in locally advanced oesophageal cancer: a systematic review and hierarchical Bayesian meta-analysis","volume":"87","author":"Dai","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"1","key":"2026052912571875200_ref7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00423-023-03091-0","article-title":"Neoadjuvant radiochemotherapy with cisplatin\/5-flourouracil or carboplatin\/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction \u2014 comparison of postoperative mortality and complications, toxicity, and pathological tumor response","volume":"408","author":"Lorenz","year":"2023","journal-title":"Langenbecks Arch Surg"},{"issue":"4","key":"2026052912571875200_ref8","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/annonc\/mdw010","article-title":"A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction","volume":"27","author":"Klevebro","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"2026052912571875200_ref9","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/doad006","volume":"36","author":"","year":"2023","journal-title":"Dis Esophagus"},{"issue":"10184","key":"2026052912571875200_ref10","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"2026052912571875200_ref11","doi-asserted-by":"publisher","first-page":"e2425581","DOI":"10.1001\/jamanetworkopen.2024.25581","article-title":"Preoperative chemoradiotherapy vs chemotherapy for adenocarcinoma of the esophagogastric junction: a network meta-analysis","volume":"7","author":"Ronellenfitsch","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2026052912571875200_ref12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijsu.2013.12.005","article-title":"What is the best neoadjuvant regimen prior to oesophagectomy: chemotherapy or chemoradiotherapy?","volume":"12","author":"Hamilton","year":"2014","journal-title":"Int J Surg"},{"issue":"4","key":"2026052912571875200_ref13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"2026052912571875200_ref14","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1186\/s12885-025-14726-4","article-title":"Comparative analysis and optimization of tumor regression grade assessment systems in neoadjuvant therapy for esophageal squamous cell carcinoma","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Cancer"},{"issue":"5","key":"2026052912571875200_ref15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/SLA.0000000000005617","article-title":"CROSS versus FLOT regimens in esophageal and esophagogastric junction adenocarcinoma: a propensity-matched comparison","volume":"276","author":"Donlon","year":"2022","journal-title":"Ann Surg"},{"issue":"5","key":"2026052912571875200_ref16","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00432-021-03720-5","article-title":"Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis","volume":"148","author":"Plum","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2026052912571875200_ref17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000531536","article-title":"Real-world outcomes of FLOT versus CROSS regimens for patients with oesophagogastric cancers","volume":"10","author":"Shahnam","year":"2023","journal-title":"Gastrointest Tumors"},{"issue":"18","key":"2026052912571875200_ref18","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.3390\/cancers17182962","article-title":"Real-world outcomes between perioperative chemotherapy (FLOT) and preoperative concurrent chemoradiotherapy (CROSS) in localized esophageal and esophagogastric junction adenocarcinoma: a retrospective cohort study","volume":"17","author":"Wonglhow","year":"2025","journal-title":"Cancers"},{"issue":"6","key":"2026052912571875200_ref19","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1097\/SLA.0000000000000335","article-title":"What should be the gold standard for the surgical component in the treatment of locally advanced esophageal cancer: transthoracic versus rranshiatal esophagectomy","volume":"260","author":"Kutup","year":"2014","journal-title":"Ann Surg"},{"issue":"6","key":"2026052912571875200_ref20","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/SLA.0b013e3182263781","article-title":"Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta-analysis","volume":"254","author":"Boshier","year":"2011","journal-title":"Ann Surg"},{"issue":"7","key":"2026052912571875200_ref21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","article-title":"Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis","volume":"12","author":"Sjoquist","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3","key":"2026052912571875200_ref22","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.athoracsur.2022.11.027","article-title":"Robotic esophagectomy trends and early surgical outcomes: the US experience","volume":"115","author":"Khaitan","year":"2023","journal-title":"Ann Thorac Surg"},{"key":"2026052912571875200_ref23","doi-asserted-by":"publisher","first-page":"8607","DOI":"10.1007\/s00464-025-12244-9","article-title":"Comparison of utilization trends, outcomes, and costs between open and minimally invasive esophagectomy","volume":"39","author":"Tohmasi","year":"2025","journal-title":"Surg Endosc"},{"issue":"2","key":"2026052912571875200_ref24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/SLA.0000000000002171","article-title":"Minimally invasive versus open esophageal resection: three-year follow-up of the previously reported randomized controlled trial the TIME trial","volume":"266","author":"Straatman","year":"2017","journal-title":"Ann Surg"},{"issue":"4","key":"2026052912571875200_ref25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1001\/jamasurg.2020.7081","article-title":"Five-year survival outcomes of hybrid minimally invasive esophagectomy in esophageal cancer: results of the MIRO randomized clinical trial","volume":"156","author":"Nuytens","year":"2021","journal-title":"JAMA Surg"},{"issue":"4","key":"2026052912571875200_ref26","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s13304-023-01497-5","article-title":"Facing adenocarcinoma of distal esophagus and esophagogastric junction: a CROSS versus FLOT propensity score-matched analysis of oncological outcomes in a high-volume institution","volume":"75","author":"Lombardi","year":"2023","journal-title":"Updates Surg"},{"issue":"3","key":"2026052912571875200_ref27","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.rpor.2020.02.005","article-title":"Cardiotoxicity of radiation therapy in esophageal cancer","volume":"25","author":"Vo\u0161mik","year":"2020","journal-title":"Rep Pract Oncol Radiother"},{"issue":"5","key":"2026052912571875200_ref28","doi-asserted-by":"publisher","first-page":"e1026","DOI":"10.1097\/SLA.0000000000005394","article-title":"Postoperative and pathological outcomes of CROSS and FLOT as neoadjuvant therapy for esophageal and junctional adenocarcinoma: an international cohort study from the Oesophagogastric Anastomosis Audit (OGAA)","volume":"277","author":"Audit","year":"2023","journal-title":"Ann Surg"},{"key":"2026052912571875200_ref29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10388-025-01160-5","article-title":"Safety and short-term efficacy of neoadjuvant FLOT therapy in cisplatin-unfit patients with resectable esophageal squamous cell carcinoma","volume":"23","author":"Yoshinami","year":"2025","journal-title":"Esophagus."},{"issue":"2","key":"2026052912571875200_ref30","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4103\/lungindia.lungindia_126_21","article-title":"Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of taxane rechallenge","volume":"39","author":"Anoop","year":"2022","journal-title":"Lung India"},{"issue":"1","key":"2026052912571875200_ref31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13019-023-02180-x","article-title":"Minimally invasive versus open esophagectomy after neoadjuvant therapy for esophageal cancer: a meta-analysis","volume":"18","author":"Jin","year":"2023","journal-title":"J Cardiothorac Surg"},{"issue":"10","key":"2026052912571875200_ref32","doi-asserted-by":"publisher","first-page":"7914","DOI":"10.1245\/s10434-025-17945-y","article-title":"Neoadjuvant treatment and postoperative complications after surgery for esophageal cancer: a population-based, nationwide study in Finland","volume":"32","author":"Sirvi\u00f6","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"2026052912571875200_ref33","doi-asserted-by":"publisher","first-page":"e2400925","DOI":"10.1200\/PO-24-00925","article-title":"Prognostic indicators of preoperative fluorouracil, leucovorin, oxaliplatin, and docetaxel efficacy in locally advanced gastroesophageal and gastric cancer: integrating biomarker analysis and clinicopathological factors","volume":"9","author":"Jubashi","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"2026052912571875200_ref34","doi-asserted-by":"publisher","first-page":"103067","DOI":"10.1016\/j.eclinm.2024.103067","article-title":"Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands","volume":"80","author":"Van Laarhoven","year":"2025","journal-title":"eClinicalMedicine."},{"key":"2026052912571875200_ref35","doi-asserted-by":"publisher","volume-title":"Br J Surg","year":"2025","DOI":"10.1093\/bjs\/znaf056"},{"issue":"5","key":"2026052912571875200_ref36","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/SLA.0000000000002389","article-title":"Impact of lymph node yield on overall survival in patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy for cancer: a population-based cohort study in the Netherlands","volume":"266","author":"Visser","year":"2017","journal-title":"Ann Surg"},{"issue":"12","key":"2026052912571875200_ref37","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.ejso.2020.06.038","article-title":"Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: inverse propensity score weighted analysis - ClinicalKey","volume":"46","author":"Pucher","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"2026052912571875200_ref38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/bjs5.50183","article-title":"Meta-analysis of the influence of a positive circumferential resection margin in oesophageal cancer","volume":"3","author":"Evans","year":"2019","journal-title":"BJS Open"},{"issue":"9","key":"2026052912571875200_ref39","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.ejso.2017.03.001","article-title":"Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: a meta-analysis of 17 published studies","volume":"43","author":"Tomasello","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"2026052912571875200_ref40","doi-asserted-by":"publisher","first-page":"e12574","DOI":"10.7759\/cureus.12574","article-title":"Cisplatin\/5-fluorouracil (5-FU) versus carboplatin\/paclitaxel chemoradiotherapy as definitive or pre-operative treatment of esophageal cancer","volume":"13","author":"Steber","year":"2021","journal-title":"Cureus"},{"issue":"S5","key":"2026052912571875200_ref41","doi-asserted-by":"publisher","first-page":"S621","DOI":"10.21037\/jtd.2018.11.143","article-title":"The optimal neoadjuvant treatment of locally advanced esophageal cancer","volume":"11","author":"Van Der Wilk","year":"2019","journal-title":"J Thorac Dis"},{"issue":"13","key":"2026052912571875200_ref42","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/3\/doag052\/68432935\/doag052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/3\/doag052\/68432935\/doag052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:57:22Z","timestamp":1780073842000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doag052\/8698151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doag052","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,12]]},"article-number":"doag052"}}